Dr. Suresh Ratnam, MD
What this data tells you about Dr. Ratnam
Dr. Suresh Ratnam is a medical oncology in McAllen, TX, with 19 years in practice. Based on federal Medicare data, Dr. Ratnam performed 21,108 Medicare services across 2,563 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ratnam received a total of $3,000,457 from 47 pharmaceutical and/or device companies across 3167 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ratnam is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 7,650 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 3,400 | $43 | $136 |
| Contrast dye for imaging (iodine-based) | 1,900 | $0 | $3 |
| Blood draw (venipuncture) | 1,151 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,098 | $8 | $36 |
| Comprehensive metabolic blood panel | 938 | $10 | $64 |
| Epoetin alfa injection (Retacrit) for anemia | 920 | $7 | $28 |
| Lactate dehydrogenase (enzyme) level | 828 | $6 | $31 |
| Office visit, established patient (30-39 min) | 435 | $91 | $368 |
| Ferritin level test (iron stores) | 334 | $13 | $60 |
| Iron level test | 334 | $6 | $27 |
| Iron binding capacity test | 334 | $9 | $35 |
| Dexamethasone injection (steroid) | 238 | $0 | $1 |
| Office visit, established patient, complex (40-54 min) | 147 | $120 | $496 |
| Injection, fluorouracil, 500 mg | 142 | $2 | $13 |
| Reticulated (young) platelet measurement | 141 | $35 | $143 |
| Magnesium level test | 131 | $7 | $29 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 117 | $91 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 108 | $1,099 | $4,802 |
| Injection of additional new drug or substance into vein | 85 | $12 | $108 |
| Drug injection, under skin or into muscle | 76 | $11 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 76 | $97 | $707 |
| New patient office visit, complex (60-74 min) | 63 | $140 | $709 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 61 | $76 | $70 |
| Office visit, established patient (20-29 min) | 59 | $66 | $250 |
| PSA test (prostate cancer screening) | 50 | $18 | $94 |
| Irrigation of implanted venous access drug delivery device | 42 | $18 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $48 | $313 |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $49 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 27 | $22 | $157 |
| Administration of chemotherapy into vein, each additional hour | 25 | $21 | $161 |
| Ct scan of chest with contrast | 20 | $51 | $821 |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $1 | $7 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $55 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $16 | $100 |
| CT scan of chest, without contrast | 17 | $46 | $686 |
| CT scan of abdomen and pelvis with contrast | 16 | $175 | $1,067 |
| Nuclear medicine study whole body with ct scan | 14 | $1,109 | $4,929 |
| Blood creatinine level | 11 | $5 | $31 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for medical oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Ratnam is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 0%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Ratnam experienced with iron infusion (feraheme)?
Does Dr. Ratnam receive payments from pharmaceutical companies?
How do Dr. Ratnam's costs compare to other medical oncologys in McAllen?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology